Stock 688062 MABWELL (SHANGHAI) BIOSCIENCE CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

All News Mabwell (Shanghai) Bioscience Co., Ltd.

Equities

688062

CNE100005RD2

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-05-22 pm EDT 		5-day change 1st Jan Change
32.91 CNY -0.96% Intraday chart for Mabwell (Shanghai) Bioscience Co., Ltd. -2.11% +0.67%
May. 07 Mabwell Announces FDA Grants Orphan Drug Designation to 9MW2821 CI
Apr. 29 Mabwell Bioscience Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Mabwell Announces FDA Grants Orphan Drug Designation to 9MW2821
CI
Mabwell Bioscience Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Mabwell Announces MAIWEIJIAN, First Approved Biosimilar of Denosumab in China
CI
Mabwell Bioscience Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Mabwell Shanghai Bioscience Unit Gets Nod in China for Denosumab as Bone Tumor Treatment
MT
Mabwell Presents Clinical Study Data of the 9MW2821 for Patients with Cervical Cancer as Focused Plenary Oral Presentation At the Society of Gynecologic Oncology Annual Meeting
CI
Mabwell Scraps Licensing Deal With Yangtze River Pharma
MT
Mabwell Publishes Phase III Study Results of Denosumab Biosimilar in the International Top Journal of Jama Oncology
CI
Mabwell Receives IND Approval from FDA for Novel B7-H3 ADC 7Mw3711
CI
Mabwell Shanghai Bioscience Gets US FDA's Nod to Trial on Tumor Drug; Shares Jump 5%
MT
Certain A-Shares of Mabwell Bioscience Co., Ltd. are subject to a Lock-Up Agreement Ending on 18-JAN-2024.
CI
National Medical Products Administration Accepts Mabwell's 8MW0511 for Injection Accepted by NMPA
CI
Mabwell Announces the Cde Approval of Novel Nectin-4 Targeting Adc for Phase III Clinical Trial
CI
Mabwell Shanghai Bioscience Gets Nod to Trial Urothelial Cancer Drug
MT
Mabwell Announces Latest Clinical Progress and Data to be Reported on ESMO 2023 of 2 Novel Drugs
CI
Mabwell Bioscience Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Mabwell Announces First Patient Dosed in Phase Ib/II Trial of its Novel Nectin-4 Targeting ADC in Combination with PD-1 Inhibitor
CI
Mabwell Bioscience Co., Ltd.(XSSC:688062) added to S&P Global BMI Index
CI
Mabwell Bioscience Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Mabwell Bioscience Co., Ltd. Announces the U.S. FDA approval of 9MW3811 for IND
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 688062 Stock
  4. News Mabwell (Shanghai) Bioscience Co., Ltd.